PHOENIX BIOSYSTEM, INC. — Department of Health and Human Services SBIR Phase I: NIBIB

Description

DESCRIPTION provided by applicant With nearly million new infections annually sexually transmitted diseases STDs are very common in the United States And with recent changes to the national health care landscape including the passage of the Affordable Care Act and state budget cuts resulting in the closure of STD and HIV clinics primary care providers can expect to encounter more patients with STDs For women and infants STDs can have serious and long term consequences including infertility facilitation of HIV infection reproductive trac cancer pelvic inflammatory disease and poor perinatal outcomes STDs cost the US health care system nearly $ billion every year The ability to obtain easily available and sensitive Nucleic Acid Based Point Of Care POC tests in primary care clinics and inner city clinics may have a far reaching impact on the rates of STDs in this country From modeling and cost benefit analyses the bottom line for rapid accurate sensitive diagnostic tests is clear when we have them we should use them We propose to develop rapid accurate sensitive and cost effective Nucleic Acid based POC system to fulfill the unmet market needs The system can be readily expanded to include other tests in the future including HIV Viral load Hepatitis Syphilis MGen HPV and BV PUBLIC HEALTH RELEVANCE The proposed technology will have a significant commercial market worldwide for diagnosing infectious diseases including sexually transmitted diseases in non traditional settings urinary tract infections in physicianandapos s office as well as for diagnosing bloodstream infections in emergency departments ICUs Sensitive identification of pathogens can be provided quickly and that along with information on antimicrobial susceptibility patterns can be life saving or shorten the course of the infection considerably